HALEON ANZ has recently celebrated three years of becoming a standalone consumer healthcare company, following its demerger from GSK in Jul 2022.
The company behind brands such as Panadol, Voltaren, Centrum, Sensodyne and Polident is now entering its next chapter with the roll-out of a new global strategy, 'Win as One'.
With its stated purpose of delivering better everyday health with humanity remaining at the centre of Haleon's operations, the company aims to reach a billion more consumers by 2030.
It has outlined four strategic drivers to support its goals: helping more people meet their health needs; creating superior brands; using technology to pursue excellence; and building a consumer-first culture.
Reflecting on Haleon ANZ's three-year journey, GM Anish Patel said: "We've come from strong foundations and are proud to have taken that heritage and evolved it to improve the everyday health of Australian consumers, cementing our place in the Australian market.
"Looking back at the Haleon ANZ story over the past three years, we're thrilled with the progress we've made and the lives we have touched through our team, our trusted brands and our investment into research and community.
"Key to our success has been our partnership with the pharmacy and retailer communities," Patel said.
"I would like to acknowledge them and recognise the value we place on our relationships with them."
Among Haleon's achievements over the last three years are product launches that were a direct response to consumer need, including Panadol Liquid Caps, Caltrate UCII, Voltanatra, and Polident Mouth Retainer and Mouthguard.
They have also committed to a five-year fellowship program with the University of Sydney to investigate the therapeutic role of supplements in managing osteoarthritis symptoms.
"As we continue to transform Haleon into a world-class consumer company, it's clear that there is so much more potential to unlock in service of Australian consumers," Patel concluded, adding he is "excited for the next three years". KB
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Aug 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Aug 25
